Mode
Text Size
Log in / Sign up
N/A N=14 Diagnostic

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

Breast Cancer

Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Utility of Percentage Change in Longitudinal (T1) and Transverse (T2) Relaxation Times From Baseline to First Cycle of Treatment in Assessment of Response to Neo-adjuvant Chemotherapy in Breast Cancer. — -19.8; 5.4; -21.4; -7.1 Percentage change of relaxation time — p=0.046

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
3D MR Fingerprinting scan (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Case Comprehensive Cancer Center
Primary completion
Apr 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Utility of Percentage Change in Longitudinal (T1) and Transverse (T2) Relaxation Times From Baseline to First Cycle of Treatment in Assessment of Response to Neo-adjuvant Chemotherapy in Breast Cancer.
-19.8; 5.4; -21.4; -7.1 0.046 sig
PRIMARY
Longitudinal Relaxation (T1) and Transverse Relaxation (T2) Times of Breast Tumor
1304.3; 1264.6; 77.0; 68.8 0.820

Summary

The purpose of this study is to determine if new methods of MRI imaging can better measure participants' response to chemotherapy treatment.

Eligibility Criteria

Inclusion Criteria

  • Biopsy proven cases of breast cancer

Exclusion Criteria

  • Patients with onlybenign lesion
  • Patients with onlyductal carcinomain situ (DCIS)
  • Patients with recurrent/ residual breast cancer in same breast
  • Pregnant women
  • Lactating Women6.Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
  • The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator
  • Patients with contraindications for MRIdue to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient.
  • Known history of severe claustrophobia
  • Patients under the age of 18
  • For patients with known history of allergic reaction to MR contrast material or abnormal kidney function (GFR < 40 mL/ min), a contrast enhanced exam will not be performed; however, a non-contrast exam may be performed in these patients.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03650803). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search